Cover Image
市場調查報告書

歐盟5國的醫療事務的評估:第二型糖尿病 (T2DM)

Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus

出版商 FirstWord 商品編碼 344324
出版日期 內容資訊 英文 PowerPoint
商品交期: 最快1-2個工作天內
價格
Back to Top
歐盟5國的醫療事務的評估:第二型糖尿病 (T2DM) Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus
出版日期: 2015年09月01日 內容資訊: 英文 PowerPoint
簡介

本報告提供第二型糖尿病 (T2DM) 治療藥的主要10項產品相關的醫療事務 (MA) 隊伍以歐洲的150名醫生為對象的調查,最重要的MA提供內容,最受尊重的MA團隊和其他團隊的差異,對MA提供內容的滿意度,愛好的傳達手段,改善的機會等相關彙整。

調查內容

  • MA提供的最有價值的內容為何?
  • 最受尊重的MA團隊為何?與其他團隊的差異為何?
  • 是否從MA取得充分必要的資訊、愛好的傳達手段為何?
  • 貴社利用的MA團隊與競爭團隊的差異為何?
  • 貴社的MA團隊成功之處為何?改善的機會為何?

調查目標產品

  • AstraZeneca
    • Forxiga (dapagliflozin)
  • Boehringer Ingelheim
    • Jardiance (empagliflozin)
  • Eli Lilly
    • Trulicity (dulaglutide)
  • GlaxoSmithKline
    • Eperzan (albiglutide)
  • Johnson & Johnson
    • Invokana (canagliflozin)
  • Merck & Co.
    • Januvia (sitagliptin)
  • Novartis
    • Galvus (vildagliptin)
  • Novo Nordisk
    • Tresiba (Insulin Degludec)
  • Sanofi
    • Toujeo (Insulin glargine)
  • 武田藥品工業
    • Vipidia (alogliptin)
目錄
Product Code: 596200406

What do physicians think of Europe Medical Affairs teams in the Type 2 Diabetes Mellitus (T2DM) sector? Who gets top marks for performance and reputation? Who fails to measure up? How is your Medical Affairs team impacting your relationship with customers?

To find out, we surveyed 150 physicians from across the continent regarding ten leading T2DM products and their associated Medical Affairs teams.

What did they have to say about your team? Are you lagging or leading your competitors? Order your report now to find out.

Note that in addition to the Europe report we offer an equivalent report for the U.S. Order both and receive, at no cost, a third report clearly setting out the differences in findings between the two regions.

Key Questions Answered:

  • What Medical Affairs offerings do physicians most value, and how well is your team providing them?
  • Whose Medical Affairs teams are most respected, and how exactly do they distinguish themselves from the pack?
  • Do physicians feel they hear from your Medical Affairs team as much as they'd like to, and what media and methods do they prefer?
  • What does gap analyses reveal about your Medical Affairs team versus your competitors?
  • Where is your Medical Affairs team succeeding and where are there opportunities for improvement?

Emerging Themes:

Medical Affairs teams in T2DM are generally well received, but physicians do have several recommendations for improvement; we provide the details.

Some Medical Affairs offerings are highly desired by physicians. Others generate much less interest. We let you know where your team might make adjustments and strengthen relationships as a result.

The products leading in the marketplace don't necessarily lead in Medical Affairs. Which teams are doing their T2DM products justice? Which might be dragging them down?

This report lets you know.

Products Included in the Report:

  • AstraZeneca
    • Forxiga (dapagliflozin)
  • Boehringer Ingelheim
    • Jardiance (empagliflozin)
  • Eli Lilly
    • Trulicity (dulaglutide)
  • GlaxoSmithKline
    • Eperzan (albiglutide)
  • Johnson & Johnson
    • Invokana (canagliflozin)
  • Merck & Co.
    • Januvia (sitagliptin)
  • Novartis
    • Galvus (vildagliptin)
  • Novo Nordisk
    • Tresiba (insulin degludec)
  • Sanofi
    • Toujeo (insulin glargine)
  • Takeda
    • Vipidia (alogliptin)
Back to Top